Mereo BioPharma Group annual ebitda
2022
2023
2024
2025
Mereo BioPharma Group EBITDA Growth & History (MREO)
Mereo BioPharma Group's calculated EBITDA was −$39.5M for fiscal 2025.
View full Mereo BioPharma Group company overviewMereo BioPharma Group annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$39.5M | $7.3M | — |
| 2024 | 2024-12-31 | −$46.8M | −$18.9M | — |
| 2023 | 2023-12-31 | −$27.9M | $26.4M | — |
| 2022 | 2022-12-31 | −$54.2M | — | — |
Mereo BioPharma Group quarterly ebitda
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$6.9M | $3.5M | — |
| Q1 2026 | 2026-03-31 | −$8.6M | $2.5M | — |
| Q4 2025 | 2025-12-31 | −$8.1M | $7.2M | — |
| Q3 2025 | 2025-09-30 | −$10.0M | −$815,000 | — |
| Q2 2025 | 2025-06-30 | −$10.3M | $2.3M | — |
| Q1 2025 | 2025-03-31 | −$11.1M | −$1.3M | — |
| Q4 2024 | 2024-12-31 | −$15.3M | −$8.2M | — |
| Q3 2024 | 2024-09-30 | −$9.2M | −$303,000 | — |
| Q2 2024 | 2024-06-30 | −$12.6M | −$12.0M | — |
| Q1 2024 | 2024-03-31 | −$9.8M | $1.6M | — |
| Q4 2023 | 2023-12-31 | −$7.1M | — | — |
| Q3 2023 | 2023-09-30 | −$8.9M | — | — |
| Q2 2023 | 2023-06-30 | −$604,000 | — | — |
| Q1 2023 | 2023-03-31 | −$11.3M | — | — |
Mereo BioPharma Group ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, Mereo BioPharma Group's ebitda increased from −$54.2M to −$39.5M, a change of $14.8M. The latest reported quarter, Q2 2026, shows −$6.9M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Mereo BioPharma Group source filings ↗